Blog

Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes

Photo from Biagio Ricciuti/X

Apr 9, 2024, 13:33

Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter:

”If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes for the development of TCR-T cell therapies against ALK-positive cancers! Amazing study led by Carmen Mecca.”

Source: Biagio Ricciuti/X

AACR AACR24 ALK-positive cancers American Association for Cancer Research Biagio Ricciuti cancer Carmen Mecca cell therapies Dana-Farber Cancer Institute OncoDaily Oncology TCR clonotypes

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage